BMO Capital Reiterates Outperform on Terns Pharma, Raises Price Target to $26
Portfolio Pulse from Benzinga Newsdesk
BMO Capital has reiterated its Outperform rating on Terns Pharma and increased the price target from $19 to $26, indicating confidence in the company's future performance.
September 16, 2024 | 12:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BMO Capital has reiterated its Outperform rating on Terns Pharma and increased the price target from $19 to $26, suggesting a positive outlook for the company's stock.
The reiteration of an Outperform rating and the increase in price target from $19 to $26 by BMO Capital suggests strong confidence in Terns Pharma's future performance. This is likely to positively influence investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100